Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 6.78% is 880% above its 5-year average of 0.69%, around the middle of its 5-year range (0.29%–12.75%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.01% below its 12-month average of 9.16%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.78%.
DEBT TO ASSETS RATIO
6.78%
DEBT TO ASSETS RATIO AVG TTM
9.16%
DEBT TO ASSETS RATIO AVG 3Y
3.99%
DEBT TO ASSETS RATIO AVG 5Y
0.69%
DEBT TO ASSETS RATIO AVG 10Y
1.59%
DEBT TO ASSETS RATIO AVG 15Y
3.29%
DEBT TO ASSETS RATIO AVG 20Y
6.03%
CURRENT VS TTM AVG
-26.01%
CURRENT VS 3Y AVG
+69.89%
CURRENT VS 5Y AVG
+880.44%
CURRENT VS 10Y AVG
+326.09%
CURRENT VS 15Y AVG
+105.84%
CURRENT VS 20Y AVG
+12.45%
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+7433.55%
vs the sector median at left
Altimmune, Inc.
Market Cap
$513.41M
Debt to Assets Ratio
6.78%
TTM Avg
9.16%
3Y Avg
3.99%
5Y Avg
0.69%
Market Cap
$521.17M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$505.34M
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$526.66M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$504.04M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$528.49M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$530.71M
Debt to Assets Ratio
0.51%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Altimmune, Inc. (ALT) | $513.41M | 6.78% | 9.16% | 3.99% | 0.69% |
| Immix Biopharma, Inc. (IMMX)vs › | $521.17M | 0.00% | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $508.36M | 0.02% | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $505.34M | 0.13% | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $526.66M | 0.19% | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | 0.01% | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $528.49M | 0.00% | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $530.71M | 0.51% | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $532.96M | 0.01% | N/A | N/A | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $497.59M | 0.05% | N/A | N/A | N/A |
Debt/Assets
6.8%
Debt/Equity
0.08
Current Ratio
26.78
Interest Coverage
-57.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 6.78% |
| 2026-03-31 | 10.68% |
| 2025-12-31 | 12.75% |
| 2025-09-30 | 7.28% |
| 2025-06-30 | 8.33% |
| 2025-03-31 | 1.01% |
| 2024-12-31 | 1.21% |
| 2024-09-30 | 1.20% |
| 2024-06-30 | 1.07% |
| 2024-03-31 | 0.29% |
| 2023-12-31 | 0.32% |
| 2023-09-30 | 0.47% |
| 2023-06-30 | 0.49% |
| 2023-03-31 | 0.54% |
| 2022-12-31 | 0.54% |
| 2022-09-30 | 0.55% |
| 2022-06-30 | 0.64% |
| 2022-03-31 | 0.70% |
| 2021-12-31 | 0.70% |
| 2021-09-30 | 0.69% |
| 2021-06-30 | 0.64% |
| 2021-03-31 | 0.66% |
| 2020-12-31 | 0.74% |
| 2020-09-30 | 0.81% |
| 2020-06-30 | 2.19% |
| 2020-03-31 | 3.10% |
| 2019-12-31 | 3.23% |
| 2019-09-30 | 3.39% |
| 2019-06-30 | 3.68% |
| 2019-03-31 | 3.80% |
| 2018-12-31 | 1.05% |
| 2018-09-30 | 3.81% |
| 2018-06-30 | 3.64% |
| 2018-03-31 | 0.08% |
| 2017-12-31 | 1.03% |
| 2017-09-30 | 0.86% |
| 2017-06-30 | 0.68% |
| 2017-03-31 | 20.96% |
| 2016-12-31 | 0.22% |
| 2016-09-30 | 0.78% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 5.45% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 1.10% |
| 2015-03-31 | 1.96% |
| 2014-12-31 | 3.39% |
| 2014-09-30 | 4.25% |
| 2014-06-30 | 8.14% |
| 2014-03-31 | 10.33% |
| 2013-12-31 | 16.47% |
| 2013-09-30 | 9.58% |
| 2013-06-30 | 13.77% |
| 2013-03-31 | 17.25% |
| 2012-12-31 | 16.64% |
| 2012-09-30 | 15.61% |
| 2012-06-30 | 10.24% |
| 2012-03-31 | 13.28% |
| 2011-12-31 | 0.00% |
| 2011-09-30 | 0.00% |
| 2011-06-30 | 0.00% |
| 2011-03-31 | 0.00% |
| 2010-12-31 | 0.00% |
| 2010-09-30 | 92.80% |
| 2010-06-30 | 80.29% |
| 2010-03-31 | 64.19% |
| 2009-12-31 | 51.16% |
| 2009-09-30 | 39.50% |
| 2009-06-30 | 40.11% |
| 2009-03-31 | 33.09% |
| 2008-12-31 | 32.46% |
| 2008-09-30 | 37.45% |
| 2008-06-30 | 36.08% |
| 2008-03-31 | 32.13% |
| 2007-12-31 | 31.03% |
| 2007-09-30 | 29.90% |
| 2007-06-30 | 101.03% |
| 2007-03-31 | 0.00% |
| 2006-12-31 | 16.45% |
| 2006-09-30 | 0.00% |
| 2006-06-30 | 0.00% |
| 2006-03-31 | 0.00% |
| 2005-12-31 | 0.00% |
| 2005-09-30 | 0.00% |
| 2005-06-30 | 86.64% |
